Multidrug Resistance in a Urothelial Cancer Cell Line After 3, 1-Hour Exposures to Mitomycin C

Journal of Urology

Volumn 178, Issue 5, 2007, Pages 2171-2175

  Speers, Alan G ^a   Lwaleed, Bashir A ^c   Featherstone, Jonathan M ^b,c   Cooper, Alan J ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

bladder; bladder neoplasms; drug resistance, multiple; mitomycin; urothelium

Indexed keywords

EPIRUBICIN; MITOMYCIN C;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CLONE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG PENETRATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FOLLOW-UP STUDIES; HUMANS; INTRACELLULAR FLUID; MITOMYCIN; PHENOTYPE; SPHEROIDS, CELLULAR; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 35148877606     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.06.047     Document Type: Article

References (18)

1. Richie J.P. Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 19 (1992) 521
2. Tolley D.A., Parmar M.K., Grigor K.M., Lallemand G., Benyon L.L., Fellows J., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol 155 (1996) 1233
3. Sauna Z.E., Smith M.M., Muller M., Kerr K.M., and Ambudkar S.V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33 (2001) 481
4. Jennings A.M., Solomon L.Z., Sharpe P., Hayes M.C., Cooper A.J., and Birch B.R. Estramustine reversal of resistance to intravesical epirubicin chemotherapy. Eur Urol 35 (1999) 327
5. Lewin J.L., Cooper A., and Birch B. Progesterone: a novel adjunct to intravesical chemotherapy. BJU Int 90 (2002) 736
6. Speers A.G., Lwaleed B.A., Featherstone J.M., Sallis B.J., and Cooper A.J. Furosemide reverses multidrug resistance status in bladder cancer cells in vitro. J Clin Pathol 59 (2006) 912
7. Naito S., Kotoh S., Omoto T., Osada Y., Sagiyama K., Iguchi A., et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. Cancer Chemother Pharmacol 42 (1998) 367
8. McGovern F., Kachel T., Vijan S., Schiff S., Lin C.W., and Prout Jr. G.R. Establishment and characterization of a doxorubicin-resistant human bladder cancer cell line (MGH-U1R). J Urol 140 (1988) 410
9. Hayes M.C., Birch B.R., Cooper A.J., and Primrose J.N. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1). BJU Int 87 (2001) 245
10. Duffy P.M., Hayes M.C., Cooper A., and Smart C.J. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model. Br J Urol 77 (1996) 819
11. Duffy P.M., Hayes M.C., Gatrell S.K., Cooper A., and Smart C.J. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. Br J Urol 77 (1996) 824
12. Crook T.J., Dyer J.P., McCormick R.I., Birch B.R., and Cooper A.J. The effects of meglumine gamma linolenic acid (MeGLA) on an organ culture model of superficial bladder cancer. Urol Res 30 (2002) 59
13. Sutherland R.M. Cell and environment interactions in tumour microregions: the multicell spheroid model. Science 240 (1988) 177
14. Clifford S.C., Thomas D.J., Neal D.E., and Lunec J. Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. Br J Cancer 69 (1994) 680
15. Duffy P.M., Hayes M.C., Cooper A., and Smart C.J. Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. Br J Cancer 74 (1996) 906
16. Baucher N.R., Gordon S.L., Gee M.V., and Kon H. NADPH cytochrome P450 reductase activation of the quinine anticancer agents to free radicals. Proc Natl Acad Sci U S A 76 (1979) 954
17. Liu L.F., Rowe T.C., and Yang L. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258 (1983) 15365
18. Nakagawa M., Emoto A., Nasu N., Hanada T., Kuwano M., Cole S.P., et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 157 (1997) 1260